Tevogen Bio Executes 50:1 Reverse Stock Split to Meet Nasdaq Listing Requirements
Event summary
- Tevogen Bio's Board approved a 50:1 reverse stock split, effective March 6, 2026, to regain compliance with Nasdaq's $1 minimum bid price requirement.
- The split will convert every 50 shares into one share, with fractional shares compensated in cash.
- Tevogen's stock will continue trading under the symbol TVGN but with a new CUSIP number (88165K 200).
- As of January 14, 2026, Tevogen's directors and executive officers collectively owned over 70% of the company's common stock.
The big picture
Tevogen's reverse stock split is a defensive move to avoid delisting, reflecting broader challenges faced by small-cap biotech firms in maintaining market compliance. The company's reliance on AI and precision T cell therapies positions it within the competitive landscape of next-generation healthcare innovation, though financial stability remains a critical hurdle.
What we're watching
- Liquidity Impact
- How the reduced share count will affect trading liquidity and institutional investor participation.
- Operational Stability
- Whether Tevogen can sustain its business operations amid financial restructuring efforts.
- Strategic Pivot
- The pace at which Tevogen advances its broader healthcare initiatives beyond its core biotech focus.
Related topics